RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study

Autor:	Núria Díez-Padrisa, Chenjerai Jairoce, Nana Aba Williams, Benoit Gamain, Ben Gyan, James G. Beeson, Alfons Jiménez, Evelina Angov, Kwaku Poku Asante, Rebeca Santano, Deepak Gaur, Ruth Aguilar, Aintzane Ayestaran, Clarissa Valim, Ross L. Coppel, David Dosoo, Seth Owusu-Agyei, Joseph J. Campo, David E. Lanar, Itziar Ubillos, Marta Vidal, David R. Cavanagh, Augusto Nhabomba, Virander S. Chauhan, Sheetij Dutta, Carlota Dobaño, Gemma Moncunill, Chetan E. Chitnis
Přispěvatelé:	Universitat de Barcelona (UB), Centro de Investigação em Saúde de Manhiça [Maputo, Mozambique] (CISM), University of Ghana, Kintampo Health Research Centre, Ghana, CIBER de Epidemiología y Salud Pública (CIBERESP), Walter Reed Army Institute of Research, International Centre for Genetic Engineering and Biotechnology [New Delhi] (ICGEB), Biologie de Plasmodium et Vaccins - Malaria Parasite Biology and Vaccines, Institut Pasteur [Paris], Jawaharlal Nehru University (JNU), Department of Immunology and Infectious Diseases (IID), Harvard T.H. Chan School of Public Health, Biologie Intégrée du Globule Rouge (BIGR (UMR_S_1134 / U1134)), Institut National de la Transfusion Sanguine [Paris] (INTS)-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Université des Antilles (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Monash University [Melbourne], University of Edinburgh, The Macfarlane Burnet Institute for Medical Research and Public Health [Melbourne], Funding was obtained from the NIH-NIAID (R01AI095789), PATH Malaria Vaccine Initiative (MVI), Ministerio de Economía y Competitividad (Instituto de Salud Carlos III, PI11/00423 and PI14/01422), and EVIMalaR and AGAUR-Catalonia (2014 SGR991). GM was a recipient of a Sara Borrell—ISCIII fellowship (CD010/00156) and had the support of the Department of Health, Catalan Government (SLT006/17/00109). ISGlobal is a member of the CERCA Program, Generalitat de Catalunya., Biologie de Plasmodium et Vaccins, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles (UA)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Université de La Réunion (UR)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Transfusion Sanguine [Paris] (INTS), Institut Pasteur [Paris] (IP), Institut National de la Transfusion Sanguine [Paris] (INTS)-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles (UA)
Rok vydání:	2019
Předmět:	Male lcsh:Medicine Antibodies Protozoan 0302 clinical medicine Pre-erythrocytic antigens antibody RTS S Medicine 030212 general & internal medicine Malaria Falciparum Child Children Protection biology Malaria vaccine Vaccination General Medicine Acquired immune system protection 3. Good health Blood-stage antigens Child Preschool Female Infants Research Article Naturally acquired immunity Plasmodium falciparum malaria Malària Àfrica Antigens Protozoan RTS 03 medical and health sciences Immune system Antigen parasitic diseases Malaria Vaccines Humans Antibody Maternal antibodies business.industry lcsh:R Infant biology.organism_classification medicine.disease Malaria maternal antibodies Case-Control Studies Immunology Africa Antibody Formation [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology business Vaccine 030217 neurology & neurosurgery
Zdroj:	BMC Medicine Dobaño, C, Ubillos, I, Jairoce, C, Gyan, B, Vidal, M, Jiménez, A, Santano, R, Dosoo, D, Nhabomba, A J, Ayestaran, A, Aguilar, R, Williams, N A, Díez-Padrisa, N, Lanar, D, Chauhan, V, Chitnis, C, Dutta, S, Gaur, D, Angov, E, Asante, K P, Owusu-Agyei, S, Valim, C, Gamain, B, Coppel, R L, Cavanagh, D, Beeson, J G, Campo, J J & Moncunill, G 2019, ' RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children : a case-control study ', BMC Medicine, vol. 17, no. 1, 157 . https://doi.org/10.1186/s12916-019-1378-6 BMC Medicine, BioMed Central, 2019, 17 (1), pp.157. ⟨10.1186/s12916-019-1378-6⟩ Dipòsit Digital de la UB Universidad de Barcelona BMC Medicine, 2019, 17 (1), pp.157. ⟨10.1186/s12916-019-1378-6⟩ BMC Medicine, Vol 17, Iss 1, Pp 1-19 (2019) Recercat. Dipósit de la Recerca de Catalunya instname
ISSN:	1741-7015
Popis:	Background Vaccination and naturally acquired immunity against microbial pathogens may have complex interactions that influence disease outcomes. To date, only vaccine-specific immune responses have routinely been investigated in malaria vaccine trials conducted in endemic areas. We hypothesized that RTS,S/A01E immunization affects acquisition of antibodies to Plasmodium falciparum antigens not included in the vaccine and that such responses have an impact on overall malaria protective immunity. Methods We evaluated IgM and IgG responses to 38 P. falciparum proteins putatively involved in naturally acquired immunity to malaria in 195 young children participating in a case-control study nested within the African phase 3 clinical trial of RTS,S/AS01E (MAL055 NCT00866619) in two sites of different transmission intensity (Kintampo high and Manhiça moderate/low). We measured antibody levels by quantitative suspension array technology and applied regression models, multimarker analysis, and machine learning techniques to analyze factors affecting their levels and correlates of protection. Results RTS,S/AS01E immunization decreased antibody responses to parasite antigens considered as markers of exposure (MSP142, AMA1) and levels correlated with risk of clinical malaria over 1-year follow-up. In addition, we show for the first time that RTS,S vaccination increased IgG levels to a specific group of pre-erythrocytic and blood-stage antigens (MSP5, MSP1 block 2, RH4.2, EBA140, and SSP2/TRAP) which levels correlated with protection against clinical malaria (odds ratio [95% confidence interval] 0.53 [0.3–0.93], p = 0.03, for MSP1; 0.52 [0.26–0.98], p = 0.05, for SSP2) in multivariable logistic regression analyses. Conclusions Increased antibody responses to specific P. falciparum antigens in subjects immunized with this partially efficacious vaccine upon natural infection may contribute to overall protective immunity against malaria. Inclusion of such antigens in multivalent constructs could result in more efficacious second-generation multistage vaccines. Electronic supplementary material The online version of this article (10.1186/s12916-019-1378-6) contains supplementary material, which is available to authorized users.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49aac5dfbaffd6e0ed1b1225cbbfcf75 https://pubmed.ncbi.nlm.nih.gov/31409398 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.